SMTL ID : 6p8x.3 (3 other biounits)

Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.11 Å

Oligo State

monomer

Ligands

2 x CA: CALCIUM ION(Non-covalent)

CA.1: 2 residues within 4Å: Chain A: S.31 Ligands: GDP.3 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.31, H2O.1, H2O.1, H2O.1, H2O.2 CA.2: 1 residues within 4Å: Chain A: E.77 5 PLIP interactions: 2 interactions with chain A, 3 Ligand-Water interactions Metal complexes: A:E.77, A:E.77, H2O.1, H2O.2, H2O.2

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.3: 20 residues within 4Å: Chain A: A.25, C.26, G.27, V.28, G.29, K.30, S.31, A.32, F.42, V.43, D.44, N.130, K.131, D.133, L.134, S.159, A.160, K.161 Ligands: CA.1, O5V.4 23 PLIP interactions: 23 interactions with chain A Hydrogen bonds: A:A.25, A:G.27, A:V.28, A:G.29, A:K.30, A:S.31, A:A.32, A:V.43, A:Y.46, A:N.130, A:K.131, A:K.131, A:S.159, A:A.160, A:K.161 Water bridges: A:D.44, A:E.45, A:Y.46, A:Y.46 Salt bridges: A:K.30, A:D.133 pi-Stacking: A:F.42, A:F.42

1 x O5V: 2-[4-bromo-2-(3-phenyl-2,5-dihydro-1H-pyrrole-1-carbonyl)phenoxy]-N-(1-propanoylazetidin-3-yl)acetamide(Covalent)

O5V.4: 15 residues within 4Å: Chain A: V.23, G.24, C.26, K.30, A.73, G.74, Q.75, R.82, M.86, D.106, H.109, Y.110, Q.113, I.114 Ligands: GDP.3 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:V.23, A:D.106, A:H.109, A:Q.113, A:Q.113 Hydrogen bonds: A:K.30, A:A.73, A:R.82, A:Y.110 Water bridges: A:R.116 pi-Stacking: A:Y.110, A:Y.110

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Shin, Y. et al., Discovery ofN-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C. Acs Med.Chem.Lett. (2019)

Release Date

2019-08-28

Peptides

GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

GTPase KRas

Related Entries With Identical Sequence